8-K: CDT Equity Announces 1-for-25 Reverse Stock Split

CDT Equity Inc. will implement a 1-for-25 reverse stock split effective March 26, 2026, with adjusted trading beginning March 27, 2026, to maintain its Nasdaq listing.

Summary

• CDT Equity Inc. is executing a 1-for-25 reverse stock split of its common stock.
• The amendment to the Company's Second Amended and Restated Certificate of Incorporation was filed on March 24, 2026.
• The reverse stock split becomes effective on March 26, 2026, at 5:00 p.m., Eastern Time.
• Common Stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market on March 27, 2026, at market open under the existing ticker symbol, CDT.
• Every twenty-five shares of issued and outstanding common stock will be combined into one share.
• The par value of $0.0001 per share will remain unchanged.
• No fractional shares will be issued; stockholders will receive a cash payment based on the closing price on March 26, 2026.
• The post-Reverse Stock Split Common Stock CUSIP number will be 20678X502.
• The number of outstanding shares of common stock will be reduced to approximately 4,722,450 after the split.
• Proportional adjustments will be made to equity awards, convertible securities, and warrants.
• The total number of authorized shares of common stock will not be reduced from 250,000,000 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While a reverse split can be a necessary step to maintain Nasdaq listing, which is positive, it often follows a period of sustained low stock price, which can be a negative signal. The impact on long-term value is uncertain.

Positives

• The reverse stock split aims to increase the per-share price, which is often a requirement to maintain listing on Nasdaq, thus ensuring continued access to public markets.
• Stockholders previously approved the board's authority to determine split ratios and timing, indicating alignment on this strategic option.

Negatives

• Reverse stock splits can sometimes be perceived negatively by the market, potentially signaling underlying financial challenges or a lack of investor confidence that led to a low stock price.
• There is a risk that the reverse stock split may not achieve its intended effect of increasing or stabilizing the stock price, or that the price may decline again post-split.

Risks

• The effect that the reverse stock split may have on the price of the Company's common stock.
• The ability or inability to maintain the listing of CDT's securities on Nasdaq.
• The ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by competition.
• The ability of the combined company to grow and manage growth economically and hire and retain key employees.
• Risks that CDT's product candidates in development fail clinical trials or are not approved by regulatory authorities on a timely basis or at all.
• Changes in applicable laws or regulations.
• The possibility that CDT may be adversely affected by other economic, business, and/or competitive factors.

Future Outlook

The Company anticipates that the reverse stock split will help maintain its Nasdaq listing. It also continues to focus on its strategy as a data-driven biopharmaceutical development company, leveraging AI and strategic partnerships to advance therapeutic assets and create shareholder value through licensing and M&A.

Management Comments

• CDT Equity Inc. announces that its board of directors has approved a 1-for-25 reverse stock split of the Company's common stock.
• The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.
• CDT is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common strategy employed by companies, particularly in the biopharmaceutical sector, to meet minimum bid price requirements for continued listing on major exchanges like Nasdaq. This action aims to enhance the stock's appeal to institutional investors and potentially improve liquidity, aligning with broader industry efforts to maintain market visibility and access to capital.

Corporate Governance

Stakeholder Impact

• Shareholders: Will see their number of shares reduced by a factor of 25, with a proportional increase in share price. Fractional shares will be cashed out. The goal is to maintain Nasdaq listing, which benefits shareholders by preserving liquidity and market access.
• Employees: No direct impact mentioned, but continued Nasdaq listing can contribute to company stability and access to capital for operations.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• The reverse stock split will become effective on March 26, 2026, at 5:00 p.m., Eastern Time.
• Common stock is expected to begin trading on a reverse stock split-adjusted basis on Nasdaq on March 27, 2026, at market open.
• The Company's transfer agent, Continental Stock Transfer & Trust Co., will serve as the exchange agent for the reverse stock split.
• CDT Equity Inc. will continue its focus on identifying, enhancing, and advancing high-potential therapeutic assets.

Key Dates

Recommendation

The reverse stock split is a necessary corporate action to maintain Nasdaq listing, which is generally positive for market access and liquidity. However, it does not fundamentally change the company's underlying value or business operations. Investors should hold to observe the post-split trading behavior and the company's progress in its biopharmaceutical development, as the long-term impact on stock price stability and growth remains to be seen.

Keywords

Reverse Stock Split, CDT Equity Inc., Nasdaq Listing, Common Stock, Biopharmaceutical, Corporate Action, Stock Price, CUSIP, Equity Awards, Warrants